洛匹那韋/利托那韋 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "洛匹那韋/利托那韋" in Chinese language version.

refsWebsite

Global rank Chinese rank

16web.archive.org

1^st place

8nih.gov

4^th place

5^th place

5doi.org

2^nd place

23^rd place

3drugs.com

399^th place

208^th place

1canada.ca

1,712^th place

3,316^th place

1europa.eu

68^th place

209^th place

1handle.net

102^nd place

492^nd place

1medscape.com

719^th place

889^th place

1physorg.com

6,156^th place

2,342^nd place

1fda.gov

447^th place

581^st place

1theconversation.com

928^th place

1,898^th place

1msn.com

117^th place

166^th place

1reuters.com

49^th place

81^st place

1cptech.org

low place

1ft.com

210^th place

353^rd place

1archive.today

14^th place

18^th place

1aides.org

low place

aides.org (Global: low place; Chinese: low place)

People Living with HIV: Let's change the rules imposed by the pharmaceutical industry! (PDF). AIDES. 2007-07-01. （原始内容 (PDF)存档于2007-10-20）.

archive.today (Global: 14^th place; Chinese: 18^th place)

'Abbott pulls HIV drug in Thai patents protest', Financial Times (2007-03-14). [2025-06-24]. （原始内容存档于2015-05-07）.

canada.ca (Global: 1,712^th place; Chinese: 3,316^th place)

health-products.canada.ca

Kaletra Product information. Health Canada. 2019-03-19 [2020-03-18]. （原始内容存档于2020-06-03）.

cptech.org (Global: low place; Chinese: low place)

Decree of Department of Disease Control, Ministry of Public Health, regarding exploitation of patent on drugs & medical supplies by the government on combination drug between lopinavir & ritonavir (PDF). （原始内容 (PDF)存档于2011-07-17）.

doi.org (Global: 2^nd place; Chinese: 23^rd place)

Zhang L, Zhang Y, Huang SM. Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. Molecular Pharmaceutics. 19 October 2009, 6 (6): 1766–1774. PMID 19839641. doi:10.1021/mp900132e.
Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, Kati W, Stewart K, Lal R, Hsu A, Betebenner D, Korneyeva M, Vasavanonda S, McDonald E, Saldivar A, Wideburg N, Chen X, Niu P, Park C, Jayanti V, Grabowski B, Granneman GR, Sun E, Japour AJ, Leonard JM, Plattner JJ, Norbeck DW. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrobial Agents and Chemotherapy. December 1998, 42 (12): 3218–3224. PMC 106025 . PMID 9835517. doi:10.1128/AAC.42.12.3218.
Pasipanodya B, Kuwengwa R, Prust ML, Stewart B, Chakanyuka C, Murimwa T, Brophy J, Salami O, Mushavi A, Apollo T. Assessing the adoption of lopinavir/ritonavir oral pellets for HIV-positive children in Zimbabwe. Journal of the International AIDS Society. December 2018, 21 (12): e25214. PMC 6293134 . PMID 30549217. doi:10.1002/jia2.25214.
McCreary EK, Pogue JM. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infectious Diseases. April 2020, 7 (4): ofaa105. PMC 7144823 . PMID 32284951. doi:10.1093/ofid/ofaa105 .
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. The New England Journal of Medicine. May 2020, 382 (19): 1787–1799. PMC 7121492 . PMID 32187464. doi:10.1056/NEJMoa2001282 . This randomized trial found that lopinavir–ritonavir treatment added to standard supportive care was not associated with clinical improvement or mortality in seriously ill patients with Covid-19 different from that associated with standard care alone.

drugs.com (Global: 399^th place; Chinese: 208^th place)

Lopinavir and Ritonavir. The American Society of Health-System Pharmacists. [2016-11-28]. （原始内容存档于2016-12-20）.
Kaletra (lopinavir/ritonavir): Label Change - Serious Health Problems in Premature Babies. Drugs.com. （原始内容存档于2011-03-11）.
Generic Kaletra Availability. Drugs.com. [2020-02-18]. （原始内容存档于2020-02-18）.

europa.eu (Global: 68^th place; Chinese: 209^th place)

ema.europa.eu

Kaletra EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-02-18]. （原始内容存档于2020-02-18）.

fda.gov (Global: 447^th place; Chinese: 581^st place)

accessdata.fda.gov

Drug Approval Package: Kaletra (Lopinavir/Ritonavir) NDA #21-226 & 21-251. U.S. Food and Drug Administration (FDA). 2001-11-20 [2020-03-18]. （原始内容存档于2020-03-19）.

ft.com (Global: 210^th place; Chinese: 353^rd place)

'Abbott pulls HIV drug in Thai patents protest', Financial Times (2007-03-14). [2025-06-24]. （原始内容存档于2015-05-07）.

handle.net (Global: 102^nd place; Chinese: 492^nd place)

hdl.handle.net

World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. hdl:10665/371090 . WHO/MHP/HPS/EML/2023.02.

medscape.com (Global: 719^th place; Chinese: 889^th place)

FDA Issues Safety Labeling Changes for Kaletra. Medscape. 2009-04-10 [2020-03-18]. （原始内容存档于2017-09-10）.

msn.com (Global: 117^th place; Chinese: 166^th place)

Inoculating the world may mean reviving old curbs on patents. Pittsburgh Post-Gazette. Bloomberg. 2020-04-14 [2020-04-16]. （原始内容存档于2020-08-03）.

nih.gov (Global: 4^th place; Chinese: 5^th place)

ncbi.nlm.nih.gov

Zhang L, Zhang Y, Huang SM. Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. Molecular Pharmaceutics. 19 October 2009, 6 (6): 1766–1774. PMID 19839641. doi:10.1021/mp900132e.
Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, Kati W, Stewart K, Lal R, Hsu A, Betebenner D, Korneyeva M, Vasavanonda S, McDonald E, Saldivar A, Wideburg N, Chen X, Niu P, Park C, Jayanti V, Grabowski B, Granneman GR, Sun E, Japour AJ, Leonard JM, Plattner JJ, Norbeck DW. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrobial Agents and Chemotherapy. December 1998, 42 (12): 3218–3224. PMC 106025 . PMID 9835517. doi:10.1128/AAC.42.12.3218.
Pasipanodya B, Kuwengwa R, Prust ML, Stewart B, Chakanyuka C, Murimwa T, Brophy J, Salami O, Mushavi A, Apollo T. Assessing the adoption of lopinavir/ritonavir oral pellets for HIV-positive children in Zimbabwe. Journal of the International AIDS Society. December 2018, 21 (12): e25214. PMC 6293134 . PMID 30549217. doi:10.1002/jia2.25214.
McCreary EK, Pogue JM. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infectious Diseases. April 2020, 7 (4): ofaa105. PMC 7144823 . PMID 32284951. doi:10.1093/ofid/ofaa105 .
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. The New England Journal of Medicine. May 2020, 382 (19): 1787–1799. PMC 7121492 . PMID 32187464. doi:10.1056/NEJMoa2001282 . This randomized trial found that lopinavir–ritonavir treatment added to standard supportive care was not associated with clinical improvement or mortality in seriously ill patients with Covid-19 different from that associated with standard care alone.

aidsinfo.nih.gov

Adult and Adolescent Guidelines. AIDSinfo. 2006-05-04 [2006-05-06]. （原始内容存档于2006-05-06）.
What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient. AIDSinfo: Table 10. Antiretroviral Components or Regimens Not Recommended as Initial Therapy. 2019-12-18 [2020-08-26]. （原始内容存档于2020-08-31）.

dailymed.nlm.nih.gov

Kaletra- lopinavir and ritonavir tablet, film coated Kaletra- lopinavir and ritonavir solution. DailyMed. 2019-12-26 [2020-03-18]. （原始内容存档于2020-03-19）.

physorg.com (Global: 6,156^th place; Chinese: 2,342^nd place)

Foster C. Research at Argonne helps Abbott Labs develop anti-HIV drug. [2006-09-04]. （原始内容存档于2006-10-22）.

reuters.com (Global: 49^th place; Chinese: 81^st place)

Scheer S. Israel approves generic HIV drug to treat COVID-19 despite doubts. Reuters. 2020-03-19 [2020-04-16]. （原始内容存档于2020-04-14）.

theconversation.com (Global: 928^th place; Chinese: 1,898^th place)

Bonadio E, Baldini A. Drug companies should drop their patents and collaborate to fight coronavirus. The Conversation. 2020-04-01 [2025-06-24]. （原始内容存档于2020-04-10）.

web.archive.org (Global: 1^st place; Chinese: 1^st place)

Kaletra Product information. Health Canada. 2019-03-19 [2020-03-18]. （原始内容存档于2020-06-03）.
Kaletra- lopinavir and ritonavir tablet, film coated Kaletra- lopinavir and ritonavir solution. DailyMed. 2019-12-26 [2020-03-18]. （原始内容存档于2020-03-19）.
Kaletra EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-02-18]. （原始内容存档于2020-02-18）.
Lopinavir and Ritonavir. The American Society of Health-System Pharmacists. [2016-11-28]. （原始内容存档于2016-12-20）.
Adult and Adolescent Guidelines. AIDSinfo. 2006-05-04 [2006-05-06]. （原始内容存档于2006-05-06）.
What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient. AIDSinfo: Table 10. Antiretroviral Components or Regimens Not Recommended as Initial Therapy. 2019-12-18 [2020-08-26]. （原始内容存档于2020-08-31）.
FDA Issues Safety Labeling Changes for Kaletra. Medscape. 2009-04-10 [2020-03-18]. （原始内容存档于2017-09-10）.
Kaletra (lopinavir/ritonavir): Label Change - Serious Health Problems in Premature Babies. Drugs.com. （原始内容存档于2011-03-11）.
Foster C. Research at Argonne helps Abbott Labs develop anti-HIV drug. [2006-09-04]. （原始内容存档于2006-10-22）.
Drug Approval Package: Kaletra (Lopinavir/Ritonavir) NDA #21-226 & 21-251. U.S. Food and Drug Administration (FDA). 2001-11-20 [2020-03-18]. （原始内容存档于2020-03-19）.
Generic Kaletra Availability. Drugs.com. [2020-02-18]. （原始内容存档于2020-02-18）.
Bonadio E, Baldini A. Drug companies should drop their patents and collaborate to fight coronavirus. The Conversation. 2020-04-01 [2025-06-24]. （原始内容存档于2020-04-10）.
Inoculating the world may mean reviving old curbs on patents. Pittsburgh Post-Gazette. Bloomberg. 2020-04-14 [2020-04-16]. （原始内容存档于2020-08-03）.
Scheer S. Israel approves generic HIV drug to treat COVID-19 despite doubts. Reuters. 2020-03-19 [2020-04-16]. （原始内容存档于2020-04-14）.
Decree of Department of Disease Control, Ministry of Public Health, regarding exploitation of patent on drugs & medical supplies by the government on combination drug between lopinavir & ritonavir (PDF). （原始内容 (PDF)存档于2011-07-17）.
People Living with HIV: Let's change the rules imposed by the pharmaceutical industry! (PDF). AIDES. 2007-07-01. （原始内容 (PDF)存档于2007-10-20）.

洛匹那韋/利托那韋 (Chinese Wikipedia)

aides.org (Global: low place; Chinese: low place)

archive.today (Global: 14th place; Chinese: 18th place)

canada.ca (Global: 1,712th place; Chinese: 3,316th place)

health-products.canada.ca

cptech.org (Global: low place; Chinese: low place)

doi.org (Global: 2nd place; Chinese: 23rd place)

drugs.com (Global: 399th place; Chinese: 208th place)

europa.eu (Global: 68th place; Chinese: 209th place)

ema.europa.eu

fda.gov (Global: 447th place; Chinese: 581st place)

accessdata.fda.gov

ft.com (Global: 210th place; Chinese: 353rd place)

handle.net (Global: 102nd place; Chinese: 492nd place)